OxFORD Asset Management LLP acquired a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 42,735 shares of the biopharmaceutical company’s stock, valued at approximately $122,000.

A number of other hedge funds have also modified their holdings of CLDX. Vanguard Group Inc. grew its holdings in Celldex Therapeutics by 7.8% in the second quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock worth $24,143,000 after purchasing an additional 708,095 shares during the last quarter. Meditor Group Ltd grew its holdings in Celldex Therapeutics by 8.8% in the third quarter. Meditor Group Ltd now owns 6,312,700 shares of the biopharmaceutical company’s stock worth $18,054,000 after purchasing an additional 512,700 shares during the last quarter. Northern Trust Corp grew its holdings in Celldex Therapeutics by 12.2% in the second quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock worth $4,992,000 after purchasing an additional 219,661 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Celldex Therapeutics by 3.6% in the third quarter. Dimensional Fund Advisors LP now owns 861,790 shares of the biopharmaceutical company’s stock worth $2,465,000 after purchasing an additional 29,604 shares during the last quarter. Finally, State of Wisconsin Investment Board grew its holdings in Celldex Therapeutics by 11.3% in the second quarter. State of Wisconsin Investment Board now owns 835,000 shares of the biopharmaceutical company’s stock worth $2,062,000 after purchasing an additional 85,000 shares during the last quarter. 52.46% of the stock is currently owned by institutional investors.

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) opened at $2.84 on Tuesday. Celldex Therapeutics, Inc. has a one year low of $2.20 and a one year high of $4.02. The company has a market cap of $398.44, a price-to-earnings ratio of -2.81 and a beta of 2.71.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.07. Celldex Therapeutics had a negative net margin of 1,088.58% and a negative return on equity of 46.94%. The business had revenue of $3.90 million during the quarter, compared to the consensus estimate of $1.30 million. During the same period in the previous year, the firm posted ($0.29) earnings per share. The business’s revenue for the quarter was up 77.3% compared to the same quarter last year. research analysts expect that Celldex Therapeutics, Inc. will post -0.93 EPS for the current fiscal year.

Several research firms have issued reports on CLDX. WBB Securities reaffirmed a “buy” rating and issued a $10.00 price target on shares of Celldex Therapeutics in a report on Wednesday, December 6th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $9.00 price target on shares of Celldex Therapeutics in a report on Tuesday, September 26th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Celldex Therapeutics in a report on Tuesday, November 7th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. Celldex Therapeutics has a consensus rating of “Hold” and a consensus price target of $7.05.

WARNING: This story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/01/02/oxford-asset-management-llp-acquires-shares-of-42735-celldex-therapeutics-inc-cldx.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.